• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.COVID-19 与血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂治疗。
Ann Intern Med. 2020 Aug 4;173(3):237-238. doi: 10.7326/M20-3047. Epub 2020 May 15.
2
Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.血管紧张素转换酶（ACE）抑制剂与血管紧张素II受体阻滞剂对2019冠状病毒病死亡风险的比较影响
Hypertension. 2020 Aug;76(2):e15-e17. doi: 10.1161/HYPERTENSIONAHA.120.15622. Epub 2020 Jun 3.
3
Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Aug 4;173(3):W66. doi: 10.7326/L20-0887. Epub 2020 Jun 25.
4
Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.血管紧张素转换酶2与炎症消退：支持继续使用处方血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂
Mayo Clin Proc. 2020 Jul;95(7):1552-1553. doi: 10.1016/j.mayocp.2020.05.001. Epub 2020 May 21.
5
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and coronavirus.血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂与冠状病毒
J Hypertens. 2020 Jun;38(6):1190-1191. doi: 10.1097/HJH.0000000000002469.
6
Update Alert 2: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报2：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Sep 1;173(5):W87. doi: 10.7326/L20-0969. Epub 2020 Jul 23.
7
Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.心跳：肾素-血管紧张素-醛固酮阻断药物与新冠病毒疾病易感性及严重程度的相互作用
Heart. 2020 Oct;106(19):1451-1453. doi: 10.1136/heartjnl-2020-318164.
8
Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报3：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2020 Oct 6;173(7):130-131. doi: 10.7326/L20-1068. Epub 2020 Aug 26.
9
Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carries a Moderately Increased Risk of Death.在患有非新冠病毒感染相关性脓毒症的重症监护病房患者中，血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂的长期使用率很高，但死亡风险会适度增加。
Hypertension. 2020 Jun;75(6):e15-e16. doi: 10.1161/HYPERTENSIONAHA.120.15178. Epub 2020 Apr 10.
10
ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection?对抗新冠病毒：血管紧张素轴抑制在新型冠状病毒感染中能发挥作用吗？
Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17.

引用本文的文献

1
Current Understanding of Clinical Manifestations of COVID-19 in Glomerular Disease.新型冠状病毒肺炎合并肾小球疾病临床表现的当前认识
Glomerular Dis. 2021 Jul 8;1(4):250-264. doi: 10.1159/000518276. eCollection 2021 Oct.
2
Bidirectional Relationship between COVID-19 and Diabetes: Role of Renin-Angiotensin-Aldosterone System and Drugs Modulating It.2019冠状病毒病与糖尿病之间的双向关系：肾素-血管紧张素-醛固酮系统及其调节药物的作用
J Pharm Bioallied Sci. 2021 Apr-Jun;13(2):149-154. doi: 10.4103/jpbs.JPBS_508_20. Epub 2021 May 26.
3
Patterns of pharmaceuticals use during the first wave of COVID-19 pandemic in Athens, Greece as revealed by wastewater-based epidemiology.基于污水流行病学的希腊雅典 COVID-19 大流行第一波期间药物使用模式。
Sci Total Environ. 2021 Dec 1;798:149014. doi: 10.1016/j.scitotenv.2021.149014. Epub 2021 Jul 21.

本文引用的文献

1
Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对成人 SARS-CoV-2 感染的风险和影响：一项实时系统评价。
Ann Intern Med. 2020 Aug 4;173(3):195-203. doi: 10.7326/M20-1515. Epub 2020 May 15.
2
Renin-angiotensin-aldosterone system and COVID-19 infection.肾素-血管紧张素-醛固酮系统与 COVID-19 感染。
Ann Endocrinol (Paris). 2020 Jun;81(2-3):63-67. doi: 10.1016/j.ando.2020.04.005. Epub 2020 Apr 21.
3
Keeping Up With Emerging Evidence in (Almost) Real Time.紧跟（几乎）实时涌现的证据。
Ann Intern Med. 2020 Jul 21;173(2):153-154. doi: 10.7326/M20-2627. Epub 2020 May 5.
4
Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎
N Engl J Med. 2020 Jun 18;382(25):2462-2464. doi: 10.1056/NEJMe2012924. Epub 2020 May 1.
5
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
6
Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?在新冠疫情期间，血管紧张素受体阻断药物是否可能有害？
J Hypertens. 2020 May;38(5):781-782. doi: 10.1097/HJH.0000000000002450.
7
Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators.慢性心力衰竭患者停用血管紧张素转换酶抑制剂的临床后果：喹那普利的双盲、安慰剂对照研究。喹那普利心力衰竭试验研究者。
J Am Coll Cardiol. 1993 Nov 15;22(6):1557-63. doi: 10.1016/0735-1097(93)90578-o.

COVID-19 与血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂治疗。

COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.

机构信息

Media, Pennsylvania (W.G.K.).

出版信息

Ann Intern Med. 2020 Aug 4;173(3):237-238. doi: 10.7326/M20-3047. Epub 2020 May 15.

DOI:10.7326/M20-3047
PMID:32422077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7249506/
Abstract

Mackey and colleagues reported a systematic review that found high-certainty evidence that angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers are not associated with greater illness severity in patients with COVID-19. The editorialist discusses the findings and emphasizes that, unless further data show otherwise, clinicians should continue to prescribe these drugs for their standard indications in patients with COVID-19.

摘要

麦基及其同事报告了一项系统评价，该评价发现有高度确定性证据表明血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 患者的疾病严重程度增加无关。社论作者讨论了这些发现，并强调除非有进一步的数据表明情况并非如此，否则临床医生应继续根据 COVID-19 患者的标准适应证开这些药物。